Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of febuxostat in preparation of drugs to treat or prevent Cushing's syndrome

A technology for Cushing's syndrome and febuxostat, which is applied in the application field of febuxostat in the adjuvant treatment of Cushing's syndrome, can solve problems such as undisclosed febuxostat, and achieves reduction of various indicators, Improve the quality of life and improve the effect of disease

Pending Publication Date: 2019-09-20
HUISHENG MEDICAL TECH XUZHOU CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It can be seen that the existing patents do not disclose that febuxostat can treat Cushing's syndrome

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of febuxostat in preparation of drugs to treat or prevent Cushing's syndrome
  • Application of febuxostat in preparation of drugs to treat or prevent Cushing's syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] The therapeutic effect of embodiment 1 febuxostat on Cushing's syndrome

[0020] 1. Materials and methods

[0021] 1.1 Experimental objects and grouping

[0022] 20 patients with Cushing's syndrome were randomly hospitalized (Cushing group), including 6 males and 14 females, with an average age of (30.2±8.2) years and a medical history of 9 months to 15 years. In the past 6 months, he has not taken drugs that affect blood sugar, blood lipids, and blood uric acid metabolism. There was no statistically significant difference between the two groups in terms of ethnicity, gender, age, blood pressure level, body mass index (BMI) and other general information (P>0.05), and they were comparable.

[0023] 1.2 Treatment methods

[0024] For the Cushing group, febuxostat was administered orally, once a day, 80 mg each time. Fasting venous blood was collected for 12 h in the morning before administration and 2 months after administration, and blood UA, fasting blood glucose (F...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a novel use of a drug, in particular to application of febuxostat in the preparation of drugs to treat or prevent Cushing's syndrome. Researches herein show that a patient with Cushing's syndrome has insulin resistance, and uric acid is closely related to obesity, hypertension, glucose and lipid metabolism disorder, and metabolic syndromes. Researches discover that with the increase in the level of blood uric acid, occurrence of the metabolic syndromes (including Cushing's syndrome) may increase, and the metabolic syndromes are caused. Febuxostat acting as a xanthine oxidoreductase inhibitor can reduce effectively the level of serum urate and can further treat or assist in treating Cushing's syndrome.

Description

technical field [0001] The present invention relates to a new application of febuxostat, in particular to the application of febuxostat in adjuvant medicine for Cushing's syndrome. Background technique [0002] Cushing's Syndrome is a general term for diseases caused by excessive secretion of glucocorticoids (mainly cortisol) by the adrenal glands caused by various etiologies. Stretch marks, high blood pressure, secondary diabetes and osteoporosis, etc. According to the etiology and pathological changes of the pituitary and adrenal glands, it can be divided into the following three types: iatrogenic cortisolism, pituitary bilateral adrenal hyperplasia, and adrenal cortical tumors. The most common one is the clinical type caused by the hypersecretion of pituitary adrenocorticotropic hormone (ACTH), so it is also called hypercortisolism. ACTH stimulates the excessive secretion of adrenal gland hormones, which can lead to severe cardiovascular and metabolic diseases and incre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/426A61K31/4196A61K31/496A61K31/44A61K31/03A61K31/4164A61K31/568A61P5/38
CPCA61K31/426A61K31/4196A61K31/496A61K31/44A61K31/03A61K31/4164A61K31/568A61P5/38A01N2300/00A61K31/444A61K31/136A61K31/4174A61K2300/00
Inventor 何松繁
Owner HUISHENG MEDICAL TECH XUZHOU CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com